Jacques LeLorier

2.5k total citations · 2 hit papers
24 papers, 1.8k citations indexed

About

Jacques LeLorier is a scholar working on Economics and Econometrics, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Jacques LeLorier has authored 24 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Economics and Econometrics, 6 papers in Surgery and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Jacques LeLorier's work include Health Systems, Economic Evaluations, Quality of Life (12 papers), Lipoproteins and Cardiovascular Health (6 papers) and Pharmaceutical Economics and Policy (6 papers). Jacques LeLorier is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (12 papers), Lipoproteins and Cardiovascular Health (6 papers) and Pharmaceutical Economics and Policy (6 papers). Jacques LeLorier collaborates with scholars based in Canada, United States and Finland. Jacques LeLorier's co-authors include A Aïssa Benhaddad, Geneviève Grégoire, Jerry Avorn, Mark Monane, Rhonda L. Bohn, Johanne Monette, Helen Mogun, Amir Abbas Tahami Monfared, RN and Laura Venditti and has published in prestigious journals such as New England Journal of Medicine, JAMA and Clinical Therapeutics.

In The Last Decade

Jacques LeLorier

24 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Discrepancies between Meta-Analyses and Subsequent Large Randomized, Controlled Trials

1997 802 citations Jacques LeLorier, Geneviève Grégoire et al. New England Journal of Medicine profile →
Persistence of Use of Lipid-Lowering Medications

1998 548 citations Jerry Avorn, Johanne Monette et al. JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jacques LeLorier Canada	13	526	434	323	262	214	24	1.8k
Kristijan H. Kahler United States	27	583 1.1×	480 1.1×	454 1.4×	625 2.4×	164 0.8×	72	2.9k
for the Evidence-Based Medicine Working Group Canada	10	436 0.8×	264 0.6×	273 0.8×	109 0.4×	181 0.8×	10	2.3k
Abdullah Pandor United Kingdom	28	519 1.0×	664 1.5×	503 1.6×	79 0.3×	243 1.1×	81	2.5k
Lise M. Bjerre Canada	19	314 0.6×	213 0.5×	93 0.3×	74 0.3×	91 0.4×	54	1.4k
Judith M. Kramer United States	25	509 1.0×	963 2.2×	2.0k 6.2×	365 1.4×	323 1.5×	54	3.6k
Daniel Solomon United States	18	390 0.7×	519 1.2×	124 0.4×	107 0.4×	250 1.2×	51	2.1k
Antonio Addis Italy	25	290 0.6×	344 0.8×	226 0.7×	144 0.5×	145 0.7×	121	2.7k
Kristina S. Boye United States	34	942 1.8×	396 0.9×	162 0.5×	347 1.3×	88 0.4×	164	3.8k
Sanket S. Dhruva United States	26	932 1.8×	494 1.1×	645 2.0×	67 0.3×	168 0.8×	174	2.7k
Alexander C. Fanaroff United States	20	228 0.4×	407 0.9×	942 2.9×	71 0.3×	214 1.0×	104	1.8k

Countries citing papers authored by Jacques LeLorier

Since Specialization

Citations

This map shows the geographic impact of Jacques LeLorier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacques LeLorier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacques LeLorier more than expected).

Fields of papers citing papers by Jacques LeLorier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacques LeLorier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacques LeLorier. The network helps show where Jacques LeLorier may publish in the future.

Co-authorship network of co-authors of Jacques LeLorier

This figure shows the co-authorship network connecting the top 25 collaborators of Jacques LeLorier. A scholar is included among the top collaborators of Jacques LeLorier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacques LeLorier. Jacques LeLorier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

LeLorier, Jacques, Éric Latimer, Marie‐Josée Brouillette, et al.. (2022). Trajectories of systemic agent use and associated depression- and anxiety-related health care costs among patients with psoriasis. JAAD International. 9. 11–22. 2 indexed citations

Mitchell, Dominic, Jason R. Guertin, Anick Dubois, et al.. (2018). A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention. Molecular Diagnosis & Therapy. 22(2). 241–254. 10 indexed citations

Mitchell, Dominic, et al.. (2016). Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin. Molecular Diagnosis & Therapy. 21(1). 95–105. 15 indexed citations

LeLorier, Jacques, et al.. (2015). Bias within economic evaluations – the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug. ClinicoEconomics and Outcomes Research. 7. 497–497. 8 indexed citations

Rieckmann, Peter, Alexey Boyко, Diego Centonze, et al.. (2015). Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group. Multiple Sclerosis and Related Disorders. 4(3). 202–218. 74 indexed citations

Durand, Madéleine, et al.. (2015). Cost Effectiveness of ‘On Demand’ Hiv Pre‐Exposure Prophylaxis for Non‐Injection Drug‐Using Men Who Have Sex with Men in Canada. Canadian Journal of Infectious Diseases and Medical Microbiology. 26(1). 23–29. 38 indexed citations

Guertin, Jason R., Jacques LeLorier, Madéleine Durand, et al.. (2014). Impact of a restrictive drug access program on the risk of cardiovascular encounters in children exposed to ADHD medications.. PubMed. 21(3). e357–69. 3 indexed citations

Dorais, Marc, Diana Chirovsky, Baishali Ambegaonkar, et al.. (2010). Utilization patterns of extended-release niacin in Canada: Analysis of an administrative claims database. Canadian Journal of Cardiology. 26(7). e229–e235. 12 indexed citations

LeLorier, Jacques, et al.. (2008). Drug Reimbursement Policies in Canada—Need for Improved Access to Critical Therapies. Annals of Pharmacotherapy. 42(6). 869–873. 10 indexed citations

10.

LeLorier, Jacques & Nigel S. B. Rawson. (2007). Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand. Canadian Journal of Cardiology. 23(9). 711–718. 2 indexed citations

11.

Breton, Marie-Claude, Jacques LeLorier, Amélie Forget, & Lucie Blais. (2007). Use of combination therapy in asthma: Are they prescribed according to guidelines. Respiratory Medicine. 101(9). 1916–1923. 11 indexed citations

12.

Cardinal, Héloïse, Amir Abbas Tahami Monfared, Marc Dorais, & Jacques LeLorier. (2005). The concept of the ‘percent wasted patients’ in preventive health strategies. Pharmacoepidemiology and Drug Safety. 15(1). 57–61. 12 indexed citations

13.

LeLorier, Jacques, et al.. (2005). A Willingness-To-Pay Assessment of Parents?? Preference for Shorter Duration Treatment of Acute Otitis Media in Children. PharmacoEconomics. 23(12). 1243–1255. 11 indexed citations

14.

Soulez, Gilles, Éric Thérasse, Amir Abbas Tahami Monfared, et al.. (2005). Pain and Quality of Life Assessment after Endovascular Versus Open Repair of Abdominal Aortic Aneurysms in Patients at Low Risk. Journal of Vascular and Interventional Radiology. 16(8). 1093–1100. 52 indexed citations

15.

Monfared, Amir Abbas Tahami & Jacques LeLorier. (2005). Accuracy and validity of using medical claims data to identify episodes of hospitalizations in patients with COPD. Pharmacoepidemiology and Drug Safety. 15(1). 19–29. 34 indexed citations

16.

LeLorier, Jacques. (2001). The science of health technology assessment--clinical effectiveness of therapeutic interventions.. PubMed. 8 Suppl A. 21A–23A. 5 indexed citations

17.

LeLorier, Jacques, et al.. (2000). Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis. Clinical Therapeutics. 22(1). 140–151. 25 indexed citations

18.

Birnbaum, Howard G., et al.. (1999). Using Healthcare Claims Data for Outcomes Research and Pharmacoeconomic Analyses. PharmacoEconomics. 16(1). 1–8. 95 indexed citations

19.

Avorn, Jerry, Johanne Monette, Rhonda L. Bohn, et al.. (1998). Persistence of Use of Lipid-Lowering Medications. JAMA. 279(18). 1458–1458. 548 indexed citations breakdown →

20.

LeLorier, Jacques, et al.. (1997). Discrepancies between Meta-Analyses and Subsequent Large Randomized, Controlled Trials. New England Journal of Medicine. 337(8). 536–542. 802 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact